Nose dry powder inhalation and preparation method thereof
Through nasal administration, nasal powder aerosol combined with carriers such as cyclodextrin solves the problem that volatile oils in traditional Chinese medicine are difficult to enter brain tissue, achieve the effect of quickly relieving headaches, and improves bioavailability and stability.
Patent Information
- Application Number
- CN202411204837.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-29
AI Technical Summary
Because of its high volatile and hydrophobic nature, traditional Chinese medicine volatile oils are difficult to effectively enter brain tissue through oral administration, resulting in low bioavailability and slow onset speed, and unable to quickly relieve headaches.
Using a new drug delivery method for nasal powder atomizer, using cyclodextrin or its metal organic framework as a carrier, combining menthenone, oxolactone and menthol, directly enters the brain through the nasal cavity to avoid gastrointestinal absorption , improve the bioavailability and stability of drugs.
Nasal powder mist can be absorbed quickly, take effect quickly, and reach the brain directly, significantly improving the stability and bioavailability of traditional Chinese medicine. It is suitable for relieving headaches and is easy to carry. It is suitable for the treatment of acute headaches.
Smart Images

Figure BDA0005018739360000061 
Figure BDA0005018739360000071 
Figure BDA0005018739360000091
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of nasal medicines, and in particular relates to a nasal powder spray and a preparation method thereof. Background Art
[0002] Traditional Chinese medicine dosage forms include pills, powders, decoctions, etc., which have their unique charm in the thousands of years of development history of Chinese medicine. With the continuous updating of modern technology and equipment, the traditional Chinese medicine dosage forms are continuously optimized, which is conducive to the development and promotion of Chinese medicine. Headache is one of the common clinical diseases, which may be accompanied by nausea and vomiting, affecting the effect of oral administration. Therefore, it is of great significance to develop a drug administration method that is convenient and conducive to relieving headaches.
[0003] Pulegone, ligustilide, and menthol are the main components of volatile oils of Nepeta, Angelica, and Mentha, respectively. Due to their good lipid solubility and volatility, volatile oils of traditional Chinese medicine can cross the blood-brain barrier through passive diffusion or carrier-mediated transport, thereby entering the brain tissue to relieve headaches. When administered orally, due to the high volatility and hydrophobicity of volatile oils, their solubility in digestive juices is low, resulting in reduced bioavailability, poor stability, and slow onset of action. Summary of the invention
[0004] In order to solve the above problems, a new administration method and dosage form are sought to further improve its stability and bioavailability, especially to directly enter the brain from the administration site, so as to avoid the problems of slow onset and low bioavailability caused by the need to be absorbed into the blood through the gastrointestinal tract and then pass through the blood-brain barrier to enter the brain. A powder inhaler is prepared using a carrier material suitable for volatile oils, which is administered through the nasal cavity and directly enters the brain through the nasal cavity to exert its effects. The present invention provides a nasal powder inhaler that can provide a more popular prescription for headache patients. It is a new dosage form developed on the basis of traditional Chinese medicine dosage forms, which has the characteristics of convenient medication, non-invasiveness, targeted drug delivery, etc., and is helpful for the daily prevention and treatment of headache-related diseases.
[0005] The present invention is achieved by: a nasal powder spray, comprising a pharmaceutical composition and a carrier, wherein the ratio of the pharmaceutical composition to the carrier is V 药物组合物 Milliliters / m 载体 Gram number = 1:8-1:12, the pharmaceutical composition comprises the following components: 1-10 parts by weight of pulegone, 1-10 parts by weight of ligustilide, and 3-30 parts by weight of menthol.
[0006] The carrier is one or more compositions of cyclodextrin or cyclodextrin metal organic framework.
[0007] The cyclodextrin is one or more combinations of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and hydroxypropyl-beta-cyclodextrin, and the cyclodextrin metal-organic framework is one or more combinations of alpha-cyclodextrin metal-organic framework, beta-cyclodextrin metal-organic framework, gamma-cyclodextrin metal-organic framework, and hydroxypropyl-beta-cyclodextrin metal-organic framework.
[0008] The metal skeleton can be one of potassium salt, sodium salt and calcium salt.
[0009] Furthermore, the pharmaceutical composition comprises the following components: 2-5 parts by weight of pulegone, 2-5 parts by weight of ligustilide, and 5-15 parts by weight of menthol.
[0010] Furthermore, the pharmaceutical composition comprises the following components: 5 parts by weight of pulegone, 5 parts by weight of ligustilide, and 10 parts by weight of menthol.
[0011] The present invention also provides a method for preparing a nasal powder spray, comprising taking pulegone, ligustilide and menthol according to the above ratio, dissolving pulegone, ligustilide and menthol in anhydrous ethanol, and mixing according to V 药物组合物 Milliliters: m 载体 The carrier and water are added in a ratio of grams: water milliliters = 1:8-12:40-180, and the drug and the carrier are combined by grinding or ultrasonic method for 30-90 minutes. After drying, a nasal powder spray is obtained.
[0012] Further, pulegone, ligustilide, and menthol were dissolved in 3-5 times the amount of anhydrous ethanol, and the mixture was stirred at room temperature according to V 药物组合物 Milliliters: m 载体 The carrier and water are added in a ratio of grams: milliliters of water = 1:9-11:80-140, and the drug is combined with the cyclodextrin metal organic framework by stirring, grinding or ultrasonic method for 50-70 minutes, and freeze-dried or spray-dried to control the particle size of the dried product to be between 10-100 μm to obtain a nasal powder inhaler.
[0013] Further, pulegone, ligustilide, and menthol were dissolved in 4 times the amount of anhydrous ethanol, and the mixture was stirred at room temperature according to V 药物组合物 Milliliters: m 载体 Hydroxypropyl-beta-cyclodextrin metal organic framework, beta-cyclodextrin metal organic framework and water are added in a ratio of grams: milliliters of water = 1:10:100, ultrasonicated for 60 minutes to combine the drug with the carrier, freeze-dried for 48 hours, crushed, and the particle size was controlled between 10-100 μm to obtain a nasal powder inhaler.
[0014] Furthermore, the preparation process of the cyclodextrin metal-organic framework is as follows: take 320g of cyclodextrin and mix it with 100g-110g of one or more of NaOH, KOH or Ca(OH)2, add 2000-2500mL of ultrapure water, heat at 60°C to dissolve, add 2000mL of anhydrous ethanol, stir with a magnetic stirrer until clear, add 1.0-1.5g of polyethylene glycol 6000, vortex mix for 30-60min to mix it thoroughly, centrifuge at 3000rpm for 10-30min, acidify the precipitate with formic acid and ethanol solution to control the pH at 4.5-6.5, centrifuge at 3000rpm for 10-30min, dry the precipitate to obtain a cyclodextrin metal-organic framework.
[0015] The present invention provides a nasal powder spray, which can directly deliver drugs to the brain by using a new administration method, which can ensure that the drugs directly reach the target to exert therapeutic effects and avoid the first-pass effect of the liver. At the same time, nasal administration can enable the drug to be quickly absorbed, take effect quickly, and exert therapeutic effects in a short time. Nasal powder spray is a nasal preparation with strict requirements on the powder particle size. The particle size of the nasal powder spray of the present invention is controlled between 10-100μm. It has the characteristics of simple formula, easy to carry, high bioavailability and good stability. It can adsorb drug molecules, reduce the influence of the outside world on drug molecules, and improve the stability. It is suitable for symptoms such as nausea caused by headaches, which make it impossible to relieve headaches by oral administration in the short term; it can be used to treat headaches that are more urgent and cannot be treated in the short term. Patients can carry it with them and choose different treatment cycles according to the patient's condition to achieve the purpose of treating the disease. DETAILED DESCRIPTION
[0016] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments will be clearly and completely described below in combination with the embodiments of the present invention. The following embodiments are used to illustrate the present invention but are not used to limit the scope of the present invention.
[0017] Example 1
[0018] Take 40g of alpha-cyclodextrin, add 250mL of ultrapure water, heat to completely dissolve it, let it stand at room temperature until some crystals precipitate, and absorb the saturated alpha-cyclodextrin solution; take 1mL of pulegone, 1mL of ligustilide and 3mL of menthol, mix them evenly, add 20mL of anhydrous ethanol to dilute, add the above saturated alpha-cyclodextrin solution, stir for 60min, let it stand overnight to separate the layers, remove the filtrate by suction, dry the conjugate in a vacuum freeze dryer for 48h, grind the freeze-dried powder, and control the particle size to be between 10-100μm.
[0019] Example 2
[0020] Take 400g of hydroxypropyl-beta-cyclodextrin, add 2500mL of ultrapure water, heat to completely dissolve it, let it stand at room temperature until a little crystal precipitates, and absorb the saturated hydroxypropyl-beta-cyclodextrin solution; take 5mL of pulegone, 15mL of ligustilide and 15mL of menthol, mix them evenly, add 70mL of anhydrous ethanol to dilute, add the saturated hydroxypropyl-beta-cyclodextrin solution, ultrasonicate for 30min, let it stand overnight to separate, filter out the filtrate, and dry the resulting conjugate in a vacuum freeze dryer for 48h, grind the freeze-dried powder, and control the particle size to be between 10-100μm.
[0021] Example 3
[0022] Take 108g of alpha-cyclodextrin, add 1080mL of ultrapure water, heat to completely dissolve it, cool to room temperature until crystals precipitate, and absorb the supernatant; take 2mL of pulegone, 2mL of ligustilide and 5mL of menthol, mix them evenly, add 27mL of anhydrous ethanol to dilute, add the above saturated alpha-cyclodextrin solution, stir for 90min, spray dry, and control the particle size of the spray-dried powder to be between 10-100μm.
[0023] Example 4
[0024] Take 200g of alpha-cyclodextrin, add 3000mL of ultrapure water, heat to completely dissolve it, cool to room temperature until crystals precipitate, and absorb the supernatant; take 5mL of pulegone, 5mL of ligustilide and 10mL of menthol, mix them evenly, add 80mL of anhydrous ethanol to dilute, add the above saturated alpha-cyclodextrin solution, ultrasonicate for 60min, spray dry, and control the particle size of the spray-dried powder to be between 10-100μm.
[0025] Example 5
[0026] Take 100g of beta-cyclodextrin and 100g of gamma-cyclodextrin, mix them evenly, add 2400mL of ultrapure water, heat them to completely dissolve them, cool them to room temperature until crystals precipitate, and absorb the supernatant; take 5mL of pulegone, 5mL of ligustilide and 10mL of menthol, mix them evenly, add 80mL of anhydrous ethanol to dilute them, add the above-mentioned saturated mixed solution of beta-cyclodextrin and gamma-cyclodextrin, ultrasonicate for 50min, let it stand overnight to separate the layers, filter out the filtrate, and the resulting combination is a powder inhaler, which is dried in a vacuum freeze dryer for 48h to remove excess water, and the particle size of the powder inhaler is controlled to be between 10-100μm by crushing and sieving.
[0027] Example 6
[0028] Take 320g of beta-cyclodextrin, add 100g of Ca(OH)2, add 2000mL of ultrapure water, heat at 70°C to dissolve, add 2000mL of anhydrous ethanol, stir evenly with a magnetic stirrer at 65°C, add 1.5g of polyethylene glycol 6000, vortex mix for 30min to fully mix, centrifuge at 3000rpm for 15min, acidify the precipitate with formic acid and ethanol solution to control the pH at 6.0-6.5, centrifuge at 3000rpm for 20min, and dry the precipitate to obtain a beta-cyclodextrin metal-organic framework.
[0029] Example 7
[0030] Take 240g of alpha-cyclodextrin, mix evenly, add 80g of NaOH, add 1500mL of ultrapure water, heat at 60°C to dissolve, add 1500mL of anhydrous ethanol, stir evenly with a magnetic stirrer at 55°C, add 1.0g of polyethylene glycol 4000, vortex mix for 40min to fully mix, let stand overnight to separate, centrifuge at 3000rpm for 20min, and discard the supernatant; the precipitate is acidified with acetic acid and ethanol solution to control the pH at 4.5-5.0, centrifuge at 3000rpm for 10min, and dry the precipitate to obtain an alpha-cyclodextrin metal-organic framework.
[0031] Example 8
[0032] Take 640g of hydroxypropyl-beta-cyclodextrin and 220g of KOH, add 4500mL of ultrapure water to dissolve by ultrasonication, add 4000mL of anhydrous ethanol, stir at 60°C for 60min, add 2.5g of polyethylene glycol 6000, vortex mix for 50min to fully mix, centrifuge at 3000rpm for 10min, and discard the supernatant; acidify the precipitate with acetic acid and ethanol solution to control the pH at 5.0-5.5, centrifuge at 3000rpm for 10min, and dry the precipitate to obtain a hydroxypropyl-beta-cyclodextrin metal-organic framework.
[0033] Example 9
[0034] Take 320g of gamma-cyclodextrin, add 100g of Ca(OH)2, add 2500mL of ultrapure water, heat at 60°C to dissolve, add 2000mL of anhydrous ethanol, and stir with a magnetic stirrer at 55°C until clear; add 1.0g of polyethylene glycol 6000, vortex mix for 60min to fully mix, let stand overnight to separate, centrifuge at 3000rpm for 20min, and discard the supernatant; acidify the precipitate with formic acid and ethanol solution to control the pH at 5.5-6.0, centrifuge at 3000rpm for 20min, and dry the precipitate to obtain a gamma-cyclodextrin metal-organic framework.
[0035] Example 10
[0036] Take 5 mL of pulegone, 5 mL of ligustilide and 10 mL of menthol, add 80 mL of anhydrous ethanol to dissolve, then add 200 g of beta-cyclodextrin metal-organic framework and 2500 mL of water, ultrasonicate for 40 min, spray dry, and control the particle size of the spray-dried powder to be between 10-100 μm.
[0037] Embodiment 11
[0038] Take 5 mL of pulegone, 5 mL of ligustilide and 10 mL of menthol, add 60 mL of anhydrous ethanol to dissolve, then add 220 g of alpha-cyclodextrin metal-organic framework and 3000 mL of water, grind for 90 min, dry in a vacuum freeze dryer for 48 h, crush the freeze-dried powder, and control the particle size to be between 10-100 μm.
[0039] Example 12
[0040] Take 5 mL of pulegone, 5 mL of ligustilide and 10 mL of menthol, dissolve them in 40 mL of anhydrous ethanol, add 210 g of hydroxypropyl-beta-cyclodextrin metal organic framework and 2800 mL of water, grind for 80 minutes, dry in a vacuum freeze dryer for 48 hours, crush the freeze-dried powder to control the particle size between 10-100 μm, and spray dry to control the spray-dried powder particle size between 10-100 μm.
[0041] Embodiment 13
[0042] Take 5 mL of pulegone, 5 mL of ligustilide and 10 mL of menthol, dissolve them in 80 mL of anhydrous ethanol, add 100 g of hydroxypropyl-beta-cyclodextrin metal, 100 g of beta-cyclodextrin metal-organic framework, and 2000 mL of water, ultrasonicate for 60 min, dry in a vacuum freeze dryer for 48 h, crush the freeze-dried powder, and control the particle size to be between 10-100 μm.
[0043] Comparative Example
[0044] Take 5 mL of pulegone, 5 mL of ligustilide and 15 mL of menthol, mix them evenly, add half volume of anhydrous ethanol and 3 volumes of polyethylene glycol, mix them evenly by ultrasonic mixing, spray dry the mixture to remove excess water, and control the particle size of the mixture between 10-100 μm.
[0045] Verification Example 1 (Proving the efficacy of nasal powder spray in relieving headache)
[0046] The efficacy of the pharmaceutical composition of the present invention in relieving headaches was verified by a drug efficacy test. The experimental method and results are as follows:
[0047] 1. Animals and Materials
[0048] Male SPF SD rats, weighing 180 ± 220 g, were provided by the Experimental Animal Center of Shanxi Provincial People’s Hospital, license number: SCXK (Jin) 2019-0003.
[0049] 2. Test methods
[0050] After 7 days of adaptive feeding, the migraine rat model was prepared: the model group rats were intraperitoneally injected with 7 mg / kg·bw nitroglycerin solution to prepare the migraine model of the rats. The rats were observed 4 hours later. When the rats continued to have symptoms such as red ears, frequent scratching of the head, irritability, increased number of cage climbing, and tiredness and curling up for about 30 minutes, the model was successfully established. The rats were randomly divided into a migraine model group, a comparative group, an example 1 group, an example 2 group, an example 3 group, an example 4 group, and an example 5 group, with 10 rats in each group. Another 10 SD rats were intraperitoneally injected with 7 mg / kg·bw saline as a control group. During the experiment, normal saline was sprayed into the nasal cavity of the rats in the control group and the migraine model group, the comparative example group was sprayed into the nasal cavity of the comparative example pharmaceutical composition, the Example 1 group was sprayed into the nasal cavity of the rats in the Example 1 group, the Example 2 group was sprayed into the nasal cavity of the pharmaceutical composition of Example 2, the Example 3 group was sprayed into the nasal cavity of the pharmaceutical composition of Example 3, the Example 4 group was sprayed into the nasal cavity of the pharmaceutical composition of Example 4, and the Example 5 group was sprayed into the nasal cavity of the pharmaceutical composition of Example 5. The pharmaceutical compositions were all administered using a nasal powder sprayer, one spray each time.
[0051] 3. Observation of rat behavior
[0052] After the administration, the rats were housed in individual cages, and the number of head scratchings of the rats within 30 min was recorded in three randomly selected time periods, which were completed within one day and the average value was taken.
[0053] 4. Test results
[0054] As shown in Table 1, compared with the control group, the number of head scratching and cage climbing in the migraine model group rats increased significantly (P < 0.01); compared with the migraine model group, the number of head scratching in the comparative group, Example 1 group, Example 2 group, Example 3 group, Example 4 group, and Example 5 group rats decreased, but there was no significant difference (P > 0.05).
[0055] Table 1 Rat behavioral results
[0056]
[0057] Note: Compared with the control group, ##P<0.01, n=10.
[0058] 5. Conclusion
[0059] The optimal ratio of the pharmaceutical composition provided by the present invention is: 5 parts by weight of pulegone, 5 parts by weight of ligustilide, and 10 parts by weight of menthol. After the pharmaceutical composition with this ratio is administered via the nasal cavity, the number of head scratching of animals is most significantly reduced.
[0060] Verification Example 2 (Proving the residence time of the drug composition in the nasal cavity)
[0061] The residence time of the pharmaceutical composition of the present invention in the nasal cavity was verified by the efficacy test. The experimental method and results are as follows:
[0062] 1. Animals and Materials
[0063] Male SPF SD rats, weighing 180 ± 220 g, were provided by the Experimental Animal Center of Shanxi Provincial People’s Hospital, license number: SCXK (Jin) 2019-0003.
[0064] 2. Test methods
[0065] Before the experiment, 15 normal rats were randomly divided into 5 groups, fasted for 1 hour, and anesthetized rats were kept in supine position for intranasal administration. Example 2, Example 4, Example 6, Example 7 and Example 8 were sprayed into the nasal cavity of each group of rats (n=3). Then, the oropharyngeal cavity was carefully wiped with a cotton swab at 5, 10, 15, 20, 30, 40, 60, 90, and 120 minutes. The sample was diluted with the mobile phase and analyzed by HPLC. The time point when the drug was first detected in the oropharyngeal cavity was designated as the ciliary migration time.
[0066] 3. Test results
[0067] Compared with Example 2 and Example 4, the retention time of the pharmaceutical composition in Example 10, Example 11 and Example 12 in the nasal cavity was significantly prolonged, among which the retention time of the pharmaceutical composition in Example 10 in the nasal cavity was the longest.
[0068] Table 1 Results of the retention time of the drug composition in the nasal cavity
[0069]
[0070] 4. Conclusion
[0071] The beta-cyclodextrin metal organic framework (Example 10) provided by the carrier preparation method of the present invention can effectively prolong the retention time of the drug composition in the nasal cavity.
[0072] Verification Example 3 (Proving the efficacy of nasal powder spray in relieving headache)
[0073] The efficacy of the pharmaceutical composition of the present invention in relieving headaches was verified by a drug efficacy test. The experimental method and results are as follows:
[0074] 1. Animals and Materials
[0075] Male SPF SD rats, weighing 180 ± 220 g, were provided by the Experimental Animal Center of Shanxi Provincial People’s Hospital, license number: SCXK (Jin) 2019-0003.
[0076] 2. Test methods
[0077] After 7 days of adaptive feeding of rats, a migraine rat model was prepared: the model group rats were intraperitoneally injected with 7 mg / kg·bw nitroglycerin solution to prepare a rat migraine model. The rats were observed 4 hours later. When the rats continued to have symptoms such as red ears, frequent scratching of the head, irritability, increased number of cage climbing, and tired curling for about 30 minutes, the model was successfully established. Randomly divided into migraine model group, comparative example nasal administration group, Example 10 group-oral administration, Example 10 group-nasal administration and Example 13 group, 10 in each group. Another 10 SD rats were taken and intraperitoneally injected with 7 mg / kg·bw saline as the control group. During the experiment, the control group and the migraine model group rats were sprayed with saline in the nasal cavity, the comparative example group rats were sprayed with the comparative example pharmaceutical composition through the nasal cavity, the Example 10 group (oral administration) rats were sprayed with the Example 10 powder spray in the oral cavity, the Example 10 group (nasal administration) rats were sprayed with the Example 10 powder spray in the nasal cavity, and the Example 13 group rats were sprayed with the Example 13 powder spray in the nasal cavity. The pharmaceutical compositions are all administered using a nasal powder sprayer, one spray each time.
[0078] 3.1 Observation of rat behavior
[0079] After the administration, the rats were housed in individual cages, and the number of times the rats scratched their heads and climbed the cages within 30 min was recorded in three randomly selected time periods. This was completed within one day, and the average value was taken.
[0080] 3.2 Determination of pain threshold of mechanical stimulation in rats
[0081] Use a ciliary mechanical stimulation needle to stimulate the whisker pad of the rat, starting from the smallest gram weight. When the rat does not show a head retraction reaction, increase the weight by one level until the rat shows a head retraction reaction. The gram weight of the fiber needle used at this time is the mechanical stimulation pain threshold. Repeat 3 times and take the average value.
[0082] 3.3 Measurement of thermal pain threshold in rats
[0083] One hour after the mechanical stimulation pain threshold measurement, the rat was fixed on the light analgesia instrument. After it calmed down, the whisker pad of the rat was irradiated with stimulating strong light. When the rat showed a head-retracting reaction, the stimulating light was extinguished and the time taken was recorded, which was the thermal stimulation latency. This was repeated three times and the average value was taken.
[0084] 4 Test results
[0085] 4.1 Rat behavior
[0086] As shown in Table 1, compared with the control group, the number of head scratching and cage climbing of the rats in the migraine model group increased significantly (P < 0.01); compared with the migraine model group, the number of head scratching and cage climbing of the rats in the comparative group decreased, but there was no significant difference (P > 0.05), the number of head scratching and cage climbing of the rats in the oral administration group of Example 10 decreased, but there was no significant difference (P > 0.05), and the number of head scratching and cage climbing of the rats in the nasal administration group of Example 10 and Example 13 groups decreased significantly (P < 0.05 or P < 0.01). It is suggested that the headache symptoms such as headache and irritability in the migraine model rats prepared by intraperitoneal injection of nitroglycerin solution are relieved.
[0087] Table 1 Rat behavioral results
[0088]
[0089] Note: Compared with the control group, ##P<0.01; compared with the migraine model group, *P<0.05, **P<0.01, n=10.
[0090] 4.2 Determination of mechanical stimulation pain threshold and temperature pain threshold in rats
[0091] As shown in Table 2, compared with the control group, the mechanical pain threshold and thermal stimulation latency of the rats in the migraine model group were significantly reduced (P < 0.01); compared with the migraine model group, the mechanical pain threshold and thermal stimulation latency of the rats in the control group increased, but there was no significant difference (P > 0.05), the mechanical pain threshold and thermal stimulation latency of the rats in the oral administration group of Example 10 group increased, but there was no significant difference (P > 0.05), and the mechanical pain threshold and thermal stimulation latency of the rats in the nasal administration group of Example 10 group and Example 13 group increased significantly (P < 0.05 or P < 0.01). It is suggested that the nasal powder spray can significantly improve the mechanical pain threshold and thermal stimulation latency of the migraine model rats.
[0092] Table 2 Rat behavioral results
[0093]
[0094]
[0095] Note: Compared with the control group, ##P<0.01; compared with the migraine model group, *P<0.05, **P<0.01, n=10. The above is only a preferred embodiment of the present invention, so all equivalent changes or modifications made according to the structure, features and principles described in the scope of the patent application of the present invention are included in the scope of the patent application of the present invention.
[0096] 5 Conclusion
[0097] The pharmaceutical composition provided by the present invention can be used to relieve headaches, and its therapeutic effect has been verified in animal experiments. By comparing oral administration and nasal administration, it is found that the pharmaceutical composition has a better therapeutic effect after nasal administration in the short term, indicating that the nasal powder spray can quickly relieve headaches; by comparing the comparative example, Example 10 group and Example 13 group, it is found that the drug combination has different effects on relieving headaches after being combined with different carriers, which may be related to the inclusion effect of the carrier on the pharmaceutical composition, the residence time of the powder spray in the nasal cavity, and the permeability of the powder spray in the nasal cavity. The experiment verifies that the nasal powder spray prepared in Example 10 of the present invention has a better effect on relieving headaches in the short term.
Claims
1. A nasal powder inhaler, characterized in that: A nasal powder spray, comprising a pharmaceutical composition and a carrier, wherein the ratio of the pharmaceutical composition to the carrier is V 药物组合物 Milliliters: m 载体 Gram number = 1:8-1:12, the pharmaceutical composition comprises the following components: 1-10 parts by weight of pulegone, 1-10 parts by weight of ligustilide, and 3-30 parts by weight of menthol.
2. A nasal powder inhaler according to claim 1, characterized in that: The carrier is one or more compositions of cyclodextrin or cyclodextrin metal organic framework.
3. A nasal powder inhaler according to claim 2, characterized in that: The cyclodextrin is one or more combinations of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and hydroxypropyl-beta-cyclodextrin, and the cyclodextrin metal-organic framework is one or more combinations of alpha-cyclodextrin metal-organic framework, beta-cyclodextrin metal-organic framework, gamma-cyclodextrin metal-organic framework, and hydroxypropyl-beta-cyclodextrin metal-organic framework.
4. The nasal powder inhaler according to claim 1, characterized in that: The pharmaceutical composition comprises the following components: 2-5 parts by weight of pulegone, 2-5 parts by weight of ligustilide, and 5-15 parts by weight of menthol.
5. A nasal powder inhaler according to claim 4, characterized in that: The pharmaceutical composition comprises the following components: 5 parts by weight of pulegone, 5 parts by weight of ligustilide and 10 parts by weight of menthol.
6. A method for preparing a nasal powder inhaler, characterized in that: Take pulegone, ligustilide and menthol according to the ratio of claims 1 to 5, dissolve pulegone, ligustilide and menthol in anhydrous ethanol, and 药物组合物 Milliliters: m 载体 The carrier and water are added in a ratio of grams: water milliliters = 1:8-12:40-180, and the drug and the carrier are combined by grinding or ultrasonic method for 30-90 minutes. After drying, a nasal powder spray is obtained.
7. The method for preparing a nasal powder inhaler according to claim 6, characterized in that: Dissolve pulegone, ligustilide and menthol in 3-5 times the amount of anhydrous ethanol and add the mixture according to V 药物组合物 Milliliters: m 载体 The carrier and water are added in a ratio of grams: water milliliters = 1:9-11:80-140, and the drug is combined with the cyclodextrin metal organic framework by stirring, grinding or ultrasonic method for 50-70 minutes, and freeze-dried or spray-dried to control the particle size of the dried product to be between 10-100 μm to obtain a nasal powder inhaler.
8. The method for preparing a nasal powder inhaler according to claim 7, characterized in that: Dissolve pulegone, ligustilide and menthol in 4 times the amount of anhydrous ethanol and add 4 times the amount of ethanol. 药物组合物 Milliliters: m 载体 Hydroxypropyl-beta-cyclodextrin metal organic framework, beta-cyclodextrin metal organic framework and water are added in a ratio of grams: milliliters of water = 1:10:100, ultrasonicated for 60 minutes to combine the drug with the carrier, freeze-dried for 48 hours, crushed, and the particle size was controlled between 10-100 μm to obtain a nasal powder inhaler.
9. The method for preparing a nasal powder inhaler according to claim 8, characterized in that: The preparation process of the cyclodextrin metal-organic framework is as follows: 320 g of cyclodextrin is mixed with 100 g to 110 g of one or more of NaOH, KOH or Ca(OH)2, 2000 to 2500 mL of ultrapure water is added, and the mixture is heated at 60°C to dissolve, 2000 mL of anhydrous ethanol is added, and the mixture is stirred with a magnetic stirrer until clarified, 1.0 to 1.5 g of polyethylene glycol 6000 is added, and the mixture is vortexed for 30 to 60 min to be fully mixed, and the mixture is centrifuged at 3000 rpm for 10 to 30 min, and the precipitate is acidified with formic acid and ethanol solution to control the pH value to 4.5 to 6.5, and the mixture is centrifuged at 3000 rpm for 10 to 30 min, and the precipitate is dried to obtain the cyclodextrin metal-organic framework.
